PLSE
Pulse Biosciences, Inc.
$49.98
+0.89
(+1.81%)
Mkt Cap
3.46B
Volume
315,581
52W Range
12.56-58.9
Sector
Healthcare
Beta
1.57
EPS (TTM)
-1.17 USD
P/E Ratio
-12.71
Revenue (TTM)
1.19M USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 350,000 | 0 | 0 | 700,000 | 1.42M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (72.78M) | (53.59M) | (42.21M) | (58.51M) | (63.66M) | (49.74M) | (45.99M) | (37.55M) | (25.57M) | (9.52M) | (2.81M) | (474,857) |
| EPS | -1.08 | -0.92 | -0.88 | -1.72 | -2.28 | -2.14 | -2.22 | -2.20 | -1.73 | -0.86 | -0.37 | -0.19 |
| Free Cash Flow | (54.44M) | (36.47M) | (33.16M) | (47.41M) | (54.53M) | (35.81M) | (34.79M) | (24.17M) | (13.64M) | (8.12M) | (3.40M) | (252,000) |
| FCF / Share | -0.81 | -0.62 | -0.69 | -1.40 | -1.95 | -1.54 | -1.68 | -1.42 | -0.92 | -0.74 | -0.45 | -0.10 |
| Operating CF | (54.12M) | (36.34M) | (33.04M) | (47.01M) | (54.10M) | (35.37M) | (34.19M) | (23.90M) | (11.09M) | (8.05M) | (3.32M) | (173,143) |
| Total Assets | 96.11M | 132.46M | 59.15M | 77.88M | 54.25M | 41.29M | 41.91M | 70.64M | 49.82M | 26.31M | 14.33M | 17.90M |
| Total Debt | 7.53M | 8.90M | 9.14M | 75.96M | 11.25M | 11.36M | 6.72M | 0 | 0 | 0 | 0 | 0 |
| Cash & Equiv | 80.73M | 118.04M | 44.37M | 61.14M | 28.61M | 12.46M | 6.90M | 51.10M | 3.39M | 2.09M | 3.61M | 7.01M |
| Book Value | 80.66M | 114.86M | 44.36M | (2.25M) | 35.69M | 22.89M | 30.74M | 66.33M | 45.99M | 25.30M | 13.67M | 16.07M |
| Return on Equity | -0.90 | -0.47 | -0.95 | N/A | -1.78 | -2.17 | -1.50 | -0.57 | -0.56 | -0.38 | -0.21 | -0.03 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 434,000 | 401,000 | 264,000 | 86,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (24.66M) | (18.58M) | (17.43M) | (19.39M) | (19.17M) | (16.80M) | (19.39M) | (12.68M) | (11.38M) | (10.14M) | (11.93M) | (10.57M) |
| EPS | -0.36 | -0.26 | -0.26 | -0.29 | -0.28 | -0.25 | -0.33 | -0.21 | -0.20 | -0.18 | -0.22 | -0.19 |
| Free Cash Flow | (18.80M) | (14.63M) | (14.86M) | (13.10M) | (12.91M) | (13.57M) | (9.20M) | (9.06M) | (8.42M) | (9.79M) | (6.82M) | (10.51M) |
| FCF / Share | -0.27 | -0.22 | -0.22 | -0.19 | -0.19 | -0.20 | -0.16 | -0.15 | -0.15 | -0.18 | -0.12 | -0.19 |
| Operating CF | (18.71M) | (14.60M) | (14.76M) | (13.04M) | (12.81M) | (13.52M) | (9.14M) | (9.02M) | (8.39M) | (9.78M) | (6.78M) | (10.49M) |
| Total Assets | 115.56M | 81.62M | 96.11M | 108.77M | 120.25M | 133.38M | 132.46M | 93.05M | 40.43M | 49.16M | 59.15M | 65.94M |
| Total Debt | 6.77M | 7.16M | 7.53M | 7.89M | 8.24M | 8.58M | 8.90M | 8.37M | 8.64M | 8.90M | 9.14M | 9.38M |
| Cash & Equiv | 101.62M | 68.32M | 80.73M | 95.21M | 106.35M | 119.28M | 118.04M | 79.03M | 26.20M | 34.88M | 44.37M | 50.39M |
| Book Value | 99.50M | 66.30M | 80.66M | 92.69M | 104.49M | 118.45M | 114.86M | 79.13M | 26.97M | 36.29M | 44.36M | 52.15M |
| Return on Equity | -0.25 | -0.28 | -0.22 | -0.21 | -0.18 | -0.14 | -0.17 | -0.16 | -0.42 | -0.28 | -0.27 | -0.20 |
PLSE News
Pulse Biosciences' nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026
Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment
Pulse Biosciences, Inc (NASDAQ:PLSE) Stock Has Average Price Target of $50.20
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
Why Pulse Biosciences Stock Popped Today
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Deutsche Bank AG Takes Position in Pulse Biosciences, Inc $PLSE
Bank of America Corp DE Grows Stake in Pulse Biosciences, Inc $PLSE
Pulse Biosciences (NASDAQ:PLSE) Sets New 1-Year High – Here’s Why